COMMUNIQUÉS West-GlobeNewswire

DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients
26/02/2018
Press Release Montrouge, France, February 26, 2018 DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients Positive preliminary results support Viaskin Milk's potential as the [...]
DBV Technologies annonce les résultats de l'étude de Phase II de Viaskin Milk chez les patients allergiques au lait
26/02/2018
Communiqué de presse Montrouge, France, le 26 février 2018 (22h30 CET) DBV Technologies annonce les résultats de l'étude de Phase II de Viaskin Milk chez les patients allergiques au lait Les résultats préliminaires sont [...]
Flexion Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 8, 2018
26/02/2018
BURLINGTON, Mass., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN ) today announced that it will report its fourth quarter and full year 2017 financial results after the close of the U.S. [...]
EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS
26/02/2018
EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS GAITHERSBURG, Md. and LYON, France, February 26, 2018 - Emergent BioSolutions Inc. (NYSE: EBS) and [...]
EMERGENT BIOSOLUTIONS ET VALNEVA INITIENT UNE ETUDE CLINIQUE DE PHASE I POUR EVALUER LEUR CANDIDAT VACCIN CONTRE LE VIRUS ZIKA
26/02/2018
EMERGENT BIOSOLUTIONS ET VALNEVA INITIENT UNE ETUDE CLINIQUE DE PHASE I POUR EVALUER LEUR CANDIDAT VACCIN CONTRE LE VIRUS ZIKA GAITHERSBURG, Md. et LYON, France, 26 février 2018 - Emergent BioSolutions Inc. (NYSE: EBS) [...]
Almost Family Reports Fourth Quarter and Full Year 2017 Results
26/02/2018
LOUISVILLE, Ky., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Almost Family, Inc. (NASDAQ: AFAM ), a leading provider of home health and related services, announced today its financial results for the quarter and year ended [...]
Alder BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
26/02/2018
– Strong cash position to support eptinezumab development through approval and commercial launch – – Recently reported pivotal PROMISE 2 top-line data in chronic migraine demonstrates eptinezumab significantly reduced [...]
Emergent BioSolutions and Valneva Initiate Phase 1 Clinical Study to Evaluate Vaccine Candidate Against Zika Virus
26/02/2018
GAITHERSBURG, Md. and LYON, France, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS ) and Valneva SE (Euronext Paris:VLA) today announced the initiation of a Phase 1 clinical trial in the U.S. to [...]
HTG Announces New Australian Patent for Its Technology
26/02/2018
Patent covers methods of co-detecting mRNA and small non-coding RNA TUCSON, Ariz., Feb. 26, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM ), a provider of instruments, reagents, and services for [...]
OPKO Health to Announce Fourth Quarter and Year End 2017 Financial Results on March 1, 2018
26/02/2018
MIAMI, Feb. 26, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK ), plans to announce its operating and financial results for the three and twelve months ended December 31, 2017, after the close of the U.S. [...]
Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2017
26/02/2018
Preparing for mid-2018 approval and launch of volanesorsen for FCS in the US, EU and Canada Advancing the pipeline with four Phase 2 trials underway and data planned from two studies in 2018 Conference Call Webcast [...]
Antares Pharma to Present at the Raymond James & Associates 39th Annual Institutional Investors Conference
26/02/2018
EWING, N.J., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS ) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James & Associates 39th [...]
Collegium to Host Conference Call to Discuss Fourth Quarter 2017 Financial Results and Provide Corporate Update
26/02/2018
CANTON, Mass., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL ) announced today that the Company will host a conference call and live audio webcast on Wednesday, March 7, 2018 at 4:30 p.m [...]
Tyme Technologies Announces Offering of Common Stock
26/02/2018
NEW YORK, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME ) (the “Company”), a clinical-stage biotechnology company developing cancer therapeutics, today announced that it had commenced an [...]
2018 First Half Year Financial Results Webcast for Mesoblast
26/02/2018
NEW YORK and MELBOURNE, Australia, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO ) (ASX:MSB) today announced it will report financial results for the first half year ended December 31, 2017 in a [...]
Healthwise Announces Elizabeth Beem as Chief Financial Officer
26/02/2018
BOISE, Idaho, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Healthwise, a leader in evidence-based health education, technology and services, announced that Elizabeth Beem will assume the position of Chief Financial Officer (CFO). [...]
TESARO Announces Collaboration to Evaluate Combination of ZEJULA® (Niraparib) and Anti-PD-L1 Cancer Immunotherapy in Metastatic Bladder Cancer
26/02/2018
WALTHAM, Mass., Feb. 26, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO ), an oncology-focused biopharmaceutical company, today announced that it has entered into a clinical collaboration with Genentech, a member [...]
SuperSonic Imagine to present Aixplorer® Ultimate at the European Congress of Radiology (ECR 2018)
26/02/2018
AIX-EN-PROVENCE, France, Feb. 26, 2018 (GLOBE NEWSWIRE) -- SuperSonic Imagine (Euronext:SSI) (FR0010526814), a company specializing in ultrasound medical imaging, announced today it will be presenting its premium [...]
OncBioMune Provides Updates on two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer
26/02/2018
BATON ROUGE, La., Feb. 26, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary [...]

Pages